{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T11:04:16Z","timestamp":1756811056769,"version":"3.37.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T00:00:00Z","timestamp":1728691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1038\/s41440-024-01934-x","type":"journal-article","created":{"date-parts":[[2024,10,12]],"date-time":"2024-10-12T01:01:31Z","timestamp":1728694891000},"page":"650-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["An elevated level of soluble suppression of tumorigenicity 2, but not galectin-3, is associated with the presence of coronary artery disease in hypertensive patients"],"prefix":"10.1038","volume":"48","author":[{"given":"Erika","family":"Miura-Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riku","family":"Tsudome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Suematsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Tachibana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kuwano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Sugihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kokei","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuhei","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidetoshi","family":"Kamimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-ichiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,12]]},"reference":[{"key":"1934_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/S0006-291X(02)02578-0","volume":"299","author":"K Oshikawa","year":"2002","unstructured":"Oshikawa K, Yanagisawa K, Tominaga S, Sugiyama Y. ST2 protein induced by inflammatory stimuli can modulate acute lung inflammation. Biochem Biophys Res Commun. 2002;299:18\u201324.","journal-title":"Biochem Biophys Res Commun"},{"key":"1934_CR2","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.immuni.2005.09.015","volume":"23","author":"J Schmitz","year":"2005","unstructured":"Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, Mcclanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23:479\u201390.","journal-title":"Immunity"},{"key":"1934_CR3","first-page":"145","volume":"106","author":"H Villacorta","year":"2016","unstructured":"Villacorta H, Maisel AS. Soluble ST2 testing: a promising biomarker in the management of heart failure. Arq Bras Cardiol. 2016;106:145\u201352.","journal-title":"Arq Bras Cardiol"},{"key":"1934_CR4","first-page":"e240","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DJ, Drazner MH, et al. ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines. Circulation. 2013;128:e240\u2013e327.","journal-title":"Circulation"},{"key":"1934_CR5","first-page":"770","volume":"129","author":"A Tymi\u0144ska","year":"2019","unstructured":"Tymi\u0144ska A, Kap\u0142on-Cie\u015blicka A, Oziera\u0144ski K, Budnik M, Wancerz A, Sypie\u0144 P, et al. Association of galectin-3 and soluble ST2 with in-hospital and 1-year outcomes in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Pol Arch Intern Med. 2019;129:770\u201380.","journal-title":"Pol Arch Intern Med"},{"key":"1934_CR6","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1172\/JCI30634","volume":"117","author":"S Sanada","year":"2007","unstructured":"Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest. 2007;117:1538\u201349.","journal-title":"J Clin Invest"},{"key":"1934_CR7","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.amjcard.2010.09.011","volume":"107","author":"S Manzano-Fern\u00e1ndez","year":"2011","unstructured":"Manzano-Fern\u00e1ndez S, Mueller T, Pascual-Figal D, Truong QA, Januzzi JL. Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. Am J Cardiol. 2011;107:259\u201367.","journal-title":"Am J Cardiol"},{"key":"1934_CR8","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1161\/01.CIR.0000047274.66749.FE","volume":"107","author":"EO Weinberg","year":"2003","unstructured":"Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721\u201326.","journal-title":"Circulation"},{"key":"1934_CR9","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1161\/01.CIR.0000147181.65298.4D","volume":"110","author":"UC Sharma","year":"2004","unstructured":"Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110:3121\u20138.","journal-title":"Circulation"},{"key":"1934_CR10","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCHEARTFAILURE.112.971168","volume":"6","author":"L Yu","year":"2013","unstructured":"Yu L, Ruifrok WP, Meissner M, Bos EM, van Goor H, Sanjabi B, et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ Heart Fail. 2013;6:107\u201317.","journal-title":"Circ Heart Fail"},{"key":"1934_CR11","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1161\/01.CIR.91.5.1363","volume":"91","author":"JA Rumberger","year":"1995","unstructured":"Rumberger JA. Coronary calcium, as determined by electron beam computed tomography, and coronary disease on arteriogram. Eff Patient\u2019s Sex Diagnosis Circulation. Circulation. 1995;91:1363\u201367.","journal-title":"Circulation"},{"key":"1934_CR12","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/j.jacc.2003.12.014","volume":"43","author":"S Achenbach","year":"2004","unstructured":"Achenbach S. Detection of coronary stenoses by multidetector computed tomography: it\u2019s all about resolution. J Am Coll Cardiol. 2004;43:840\u20131.","journal-title":"J Am Coll Cardiol"},{"key":"1934_CR13","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1148\/radiol.2442061218","volume":"244","author":"PK Vanhoenacker","year":"2007","unstructured":"Vanhoenacker PK, Heijenbrok-Kal MH, Van Heste R, Decramer I, Van Hoe LR, Wijns W, et al. Diagnostic performance of multidetector CT angiography for assessment of coronary artery disease: meta-analysis. Radiology. 2007;244:419\u201328.","journal-title":"Radiology"},{"key":"1934_CR14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/eurheartj\/ehm544","volume":"29","author":"S Stephen","year":"2008","unstructured":"Stephen S. Cardiac computed tomography: indications, applications, limitations, and training requirements: Report of a Writing Group deployed by the Working Group Nuclear Cardiology and Cardiac CT of the European Society of Cardiology and the European Council of Nuclear Cardiology. Eur Heart J. 2008;29:531\u201356.","journal-title":"Eur Heart J"},{"key":"1934_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1253\/circj.CJ-08-0416","volume":"73","author":"R Mitsutake","year":"2009","unstructured":"Mitsutake R, Miura S, Kawamura A, Saku K. Are metabolic factors associated with coronary artery stenosis on MDCT? Circ J. 2009;73:132\u20138.","journal-title":"Circ J"},{"key":"1934_CR16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ijcard.2009.01.058","volume":"143","author":"R Mitsutake","year":"2010","unstructured":"Mitsutake R, Miura S, Zhang B, Saku K. HDL-associated factors provide additional prognostic information for coronary artery disease as determined by multi-detector row computed tomography. Int J Cardiol. 2010;143:72\u20138.","journal-title":"Int J Cardiol"},{"key":"1934_CR17","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1751-7176.2010.00412.x","volume":"13","author":"R Mitsutake","year":"2011","unstructured":"Mitsutake R, Miura S, Shiga Y, Uehara Y, Saku K. Association between hypertension and coronary artery disease as assessed by coronary computed tomography. J Clin Hypertens (Greenwich). 2011;13:198\u2013204.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"1934_CR18","doi-asserted-by":"publisher","first-page":"870","DOI":"10.5551\/jat.3889","volume":"17","author":"Y Shiga","year":"2010","unstructured":"Shiga Y, Miura S, Mitsutake R, Kawamura A, Uehara Y, Saku K. Significance of serum high-density lipoprotein cholesterol levels for diagnosis of coronary stenosis as determined by MDCT in patients with suspected coronary artery disease. J Atheroscler Thromb. 2010;17:870\u20138.","journal-title":"J Atheroscler Thromb"},{"key":"1934_CR19","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1177\/147323001103900322","volume":"39","author":"Y Shiga","year":"2011","unstructured":"Shiga Y, Miura S, Mitsutake R, Yamagishi S, Saku K. Significance of plasma levels of pigment epithelium-derived factor as determined by multidetector row computed tomography in patients with mild chronic kidney disease and\/or coronary artery disease. J Int Med Res. 2011;39:880\u201390.","journal-title":"J Int Med Res"},{"key":"1934_CR20","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s00380-014-0553-0","volume":"30","author":"A Nakamura","year":"2015","unstructured":"Nakamura A, Miura S, Shiga Y, Norimatsu K, Miyase Y, Suematsu Y, Mitsutake R, et al. Is pentraxin 3 a biomarker, a player, or both in the context of coronary atherosclerosis and metabolic factors? Heart Vessels. 2015;30:752\u201361.","journal-title":"Heart Vessels"},{"key":"1934_CR21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.jjcc.2014.07.006","volume":"65","author":"K Norimatsu","year":"2015","unstructured":"Norimatsu K, Miura S, Suematsu Y, Shiga Y, Miyase Y, Nakamura A, et al. Associations between glycated albumin or hemoglobin A1c and the presence of coronary artery disease. J Cardiol. 2015;65:487\u201393.","journal-title":"J Cardiol"},{"key":"1934_CR22","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1007\/s00380-015-0716-7","volume":"31","author":"M Yano","year":"2016","unstructured":"Yano M, Miura S, Shiga Y, Miyase Y, Suematsu Y, Norimatsu K, et al. Association between smoking habits and severity of coronary stenosis as assessed by coronary computed tomography angiography. Heart Vessels. 2016;31:1061\u20138.","journal-title":"Heart Vessels"},{"key":"1934_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00380-016-0837-7","volume":"32","author":"K Norimatsu","year":"2017","unstructured":"Norimatsu K, Kuwano T, Miura S, Shimizu T, Shiga Y, Suematsu Y, et al. Significance of the percentage of cholesterol efflux capacity and total cholesterol efflux capacity in patients with or without coronary artery disease. Heart Vessels. 2017;32:30\u20138.","journal-title":"Heart Vessels"},{"key":"1934_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1536\/ihj.17-234","volume":"59","author":"Y Ueda","year":"2018","unstructured":"Ueda Y, Shiga Y, Idemoto Y, Tashiro K, Motozato K, Koyoshi R, et al. Association between the presence or severity of coronary artery disease and pericardial fat, paracardial fat, epicardial fat, visceral fat, and subcutaneous fat as assessed by multi-detector row computed tomography. Int Heart J. 2018;59:695\u2013704.","journal-title":"Int Heart J"},{"key":"1934_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00380-018-1218-1","volume":"34","author":"D Nose","year":"2019","unstructured":"Nose D, Shiga Y, Ueda Y, Idemoto Y, Tashiro K, Suematsu Y, et al. Association between plasma levels of PCSK9 and the presence of coronary artery disease in Japanese. Heart Vessels. 2019;34:19\u201328.","journal-title":"Heart Vessels"},{"key":"1934_CR26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.jcct.2014.07.003","volume":"8","author":"J Leipsic","year":"2014","unstructured":"Leipsic J, Abbara S, Achenbach S, Cury R, Earls JP, Mancini GJ, et al. SCCT guidelines for the interpretation and reporting of coronary CT angiography: a report of the Society of Cardiovascular Computed Tomography Guidelines Committee. J Cardiovasc Comput Tomogr. 2014;8:342\u201358.","journal-title":"J Cardiovasc Comput Tomogr"},{"key":"1934_CR27","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","volume":"51","author":"GG Gensini","year":"1983","unstructured":"Gensini GG. A more meaningful scoring system for determining the severity of coronary heart disease. Am J Cardiol. 1983;51:606.","journal-title":"Am J Cardiol"},{"key":"1934_CR28","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/archinte.1916.00080130010002","volume":"17","author":"D Dubois","year":"1916","unstructured":"Dubois D, Dubois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med. 1916;17:863\u201371.","journal-title":"Arch Intern Med"},{"key":"1934_CR29","doi-asserted-by":"publisher","first-page":"105619","DOI":"10.1016\/j.biocel.2019.105619","volume":"116","author":"E Vianello","year":"2019","unstructured":"Vianello E, Dozio E, Tacchini L, Frati L, Corsi Romanelli MM. ST2\/IL-33 signaling in cardiac fibrosis. Int J Biochem Cell Biol. 2019;116:105619.","journal-title":"Int J Biochem Cell Biol"},{"key":"1934_CR30","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/jhh.2013.130","volume":"28","author":"DB Ojji","year":"2014","unstructured":"Ojji DB, Opie LH, Lecour S, Lacerda L, Adeyemi OM, Sliwa K. The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects. J Hum Hypertens. 2014;28:432\u20137.","journal-title":"J Hum Hypertens"},{"key":"1934_CR31","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1097\/HJH.0b013e32835726a3","volume":"30","author":"C Cuspidi","year":"2012","unstructured":"Cuspidi C, Rescaldani M, Sala C, Negri F, Grassi G, Mancia G. Prevalence of electrocardiographic left ventricular hypertrophy in human hypertension: an updated review. J Hypertens. 2012;30:2066\u201373.","journal-title":"J Hypertens"},{"key":"1934_CR32","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1002\/ehf2.14147","volume":"10","author":"P Wei","year":"2023","unstructured":"Wei P, Liu L, Wang X, Zong B, Liu X, Zhang M, et al. Expression of soluble ST2 in patients with essential hypertension and its relationship with left ventricular hypertrophy. ESC Heart Fail. 2023;10:303\u201310.","journal-title":"ESC Heart Fail"},{"key":"1934_CR33","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1373\/clinchem.2012.192153","volume":"58","author":"EE Coglianese","year":"2012","unstructured":"Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, McCabe EL, et al. Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem. 2012;58:1673\u201381.","journal-title":"Clin Chem"},{"key":"1934_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.ahj.2013.02.029","volume":"165","author":"AH Wu","year":"2013","unstructured":"Wu AH, Wians F, Jaffe A. Biological variation of galectin-3 and soluble ST2 for chronic heart failure: implication on interpretation of test results. Am Heart J. 2013;165:995\u20139.","journal-title":"Am Heart J"},{"key":"1934_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.5551\/jat.59832","volume":"28","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Hu M, Ma S. Association of soluble suppression of tumorigenicity with no-reflow phenomenon and long-term prognosis in patients with non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention. J Atheroscler Thromb. 2021;28:1289\u201397.","journal-title":"J Atheroscler Thromb"},{"key":"1934_CR36","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.3390\/jcm12082790","volume":"12","author":"D Chen","year":"2023","unstructured":"Chen D, Untaru R, Stavropoulou G, Assadi-Khansari B, Kelly C, Croft AJ, et al. Elevated soluble suppressor of tumorigenicity 2 predict hospital admissions due to major adverse cardiovascular events (MACE). J Clin Med. 2023;12:2790.","journal-title":"J Clin Med"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01934-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01934-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01934-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T23:03:01Z","timestamp":1738710181000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-024-01934-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,12]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1934"],"URL":"https:\/\/doi.org\/10.1038\/s41440-024-01934-x","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"type":"print","value":"0916-9636"},{"type":"electronic","value":"1348-4214"}],"subject":[],"published":{"date-parts":[[2024,10,12]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"SM has received honoraria from Daiichi Sankyo, Otsuka Pharma, and Novartis Pharma, scholarships from Abbott Medical and Sumitomo Pharma, and research grants from AMGEN, Bayer Yakuhin, Novo Nordisk Pharma, and MSD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}